---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-133086"
form_type: "8-K"
ticker: "ANNX"
cik: "0001528115"
company_name: "Annexon, Inc."
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T18:00:36.083507+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Annexon presents positive Phase 2 data for ANX007 in GA; plans Phase 3 trials in 2024

## Summary
- ANX007 showed 73% relative risk reduction in BCVA 15-letter loss at 12 months in Phase 2 ARCHER trial.
- Statistically significant slowing of low luminance visual acuity loss and reduction in photoreceptor loss observed.
- No choroidal neovascularization increase and no cases of vasculitis; generally well-tolerated safety profile.
- Global pivotal Phase 3 ARCHER II (vs sham) expected mid-2024; Phase 3 ARROW (vs SYFOVRE) expected H2 2024.
- Preclinical data show C1q blockade protects photoreceptor synapses and preserves retinal function in GA models.

## SEC filing metadata
- accession: 0001193125-24-133086
- form_type: 8-K
- ticker: ANNX
- cik: 0001528115
- company_name: Annexon, Inc.
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1528115/000119312524133086/0001193125-24-133086-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1528115/000119312524133086/d825274d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-133086
- JSON: https://secwatch.observer/filing/0001193125-24-133086.json
- Plain text: https://secwatch.observer/filing/0001193125-24-133086.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.